Artivion, Inc. (NYSE:AORT) Stock Has Consensus Price Target of $44.83 According to Analysts

Artivion, Inc. (NYSE:AORT) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $44.83.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Needham & Company LLC reissued a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Finally, Canaccord Genuity Group upped their price objective on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 977 shares of Artivion stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares of the company’s stock, valued at $5,245,521.82. The trade was a 0.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James P. Mackin sold 70,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. The trade was a 7.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 90,460 shares of company stock worth $2,557,366. 6.30% of the stock is owned by corporate insiders.

Institutional Trading of Artivion

A number of large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its holdings in shares of Artivion by 112.5% in the 2nd quarter. Squarepoint Ops LLC now owns 63,384 shares of the company’s stock worth $1,424,000 after acquiring an additional 33,554 shares during the last quarter. Arizona State Retirement System increased its stake in Artivion by 6.2% in the 2nd quarter. Arizona State Retirement System now owns 11,709 shares of the company’s stock worth $263,000 after purchasing an additional 684 shares in the last quarter. Corient Private Wealth LP purchased a new position in Artivion in the 2nd quarter worth about $3,581,000. Susquehanna International Group LLP raised its holdings in Artivion by 584.1% during the 2nd quarter. Susquehanna International Group LLP now owns 102,531 shares of the company’s stock worth $2,304,000 after buying an additional 87,544 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Artivion by 65.9% during the 2nd quarter. Van ECK Associates Corp now owns 10,749 shares of the company’s stock worth $242,000 after buying an additional 4,269 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Artivion Stock Down 1.4%

AORT stock opened at $22.70 on Friday. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a 50 day simple moving average of $26.20 and a 200-day simple moving average of $27.83. The company has a market capitalization of $1.11 billion, a P/E ratio of -324.20 and a beta of 1.25. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, equities research analysts predict that Artivion will post 0.45 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.